FDA 483 - J. Robert Flamini - March 11, 2024

An FDA inspection of J. Robert Flamini, a clinical investigator in Atlanta, GA, revealed a significant deviation from an investigational plan. Specifically, a pediatric subject in a study for partial-onset seizures was administered an incorrect dosage of the investigational product over an extended period. This indicates a failure to conduct the study in accordance with the approved protocol.